Online inquiry

IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15832MR)

This product GTTS-WQ15832MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&SSTR2 gene. The antibody can be applied in Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001050.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6752
UniProt ID P07766; P30874
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15832MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5631MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ2398MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ6647MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ499MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ14748MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ14995MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ14000MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10113MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW